STUDY OF RELATIONSHIP BETWEEN HBV BCP/PC REGION QUASISPECIES WITH RELAPSE IN CHB PATIENTS WITH LAMIV

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户:wo19881026
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background:To investigate the relationship between HBV DNA BCP/PC region quasispecies features with relapse until meeting endpoint criteria in CHB patients with LAM treatment Methods:43 CHB patients liver biopsy samples were assessed who had met the endpoint criteria of 2008 APASL,including 2 groups:25 patients with LAM-naive treatment,18 with NAs retreatment who had received LAM-naive treatment.Serum were collected at baseline of treatment and relapse.HBV rcDNA and cccDNA were cloned into plasmid and transformed into competent cells.Selected 20 to 32 of positive clones for sequencing randomly.
其他文献
Background:To study the function of TH1/TH2 types cell in chronic hepatitis B(CHB)patients during the treatment by autologous cytokine-induced kill cells combined with nucleoside(acid) analogues of an
会议
Background:5 %-10 %Hepatitis B vaccinees produce an inadequate neutralizing antibody response following receipt of the standard vaccination regime.Genetic predisposition has been discovered to be one
会议
Background:Genetic studies have been conducted to investigate host susceptibility of the hepatitis B virus(HBV) infection;SNPs in the HLA region(6p21) were mostly reported associated with the disease
会议
Background:We investigated whether the concept of virologic breakthrough suggested by current guidelines or literatures is appropriate for treatment with entecavir(ETV) in the era of sensitive HBV DNA
会议
Background:An important goal in the treatment of chronic hepatitis B virus(HBV) infection is to prevent hepatocellular carcinoma and liver cirrhosis by suppressing HBV replication.
会议
Background:The EFFORT study have concluded that adjusting treatment strategy is recommended for suboptimal virological responders to telbivudine(LdT) at week 24,adding on adefovir(ADV) can benefit the
会议
Background:This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1(PEG-Tα1),a new long immunomodulator(Category 1.1 of Chemical Drugs) being developed from Hansoh Pharma
会议
Background:To investigate the course and efficacy of sequential PEG-IFN treatment for poor effect of HBeAg positive chronic hepatitis B patients treated with nucleos(t)ide analogue.
会议
Background:Discuss differences between early cirrhosis and no cirrhosis patients in chronic hepatitis B(CHB)patients at HBV genotypes and nontraumatic indexs commonly used in clinical.
会议
BACKGROUND & AIMS:Traditional Chinese medicine(TCM),Biejiaruangan Compound(BJRGC),containing Carapax trionycis,Cordyceps sinensis and other 9 herbs has been used to treat liver fibrosis for almost two
会议